electroCore logo
electroCore ECOR
$ 9.63 1.54%
report update icon

Quarterly report 2026-Q2
added 08-06-2026

electroCore Cash Flow 2025-2011 | ECOR

Brief cash flow overview of electroCore

This overview follows the five latest available annual observations in the 2021–2025 interval.

Operating cash flow is negative at -$8.2 million, leaving internal funding capacity weak.

Only 0 of five annual observations were positive, indicating weak repeatability.

Overall assessment

electroCore's cash flows remain vulnerable. Negative or unstable generation materially reduces financial flexibility.

Annual Cash Flow electroCore

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

-8.19 M -6.95 M -14.7 M -16.6 M -13.6 M -20.1 M -45.1 M -47.1 M -25.3 M - - - - - -

Depreciation & Amortization

501 K 760 K 962 K 548 K 382 K 399 K 250 K 66.7 K 32.3 K - - - - - -

Accounts Payables

2.71 M 1.83 M 2.16 M 2.13 M 938 K 2.08 M 5.21 M 2.7 M - - - - - - -

Accounts Receivables

1.03 M 1.37 M 717 K 401 K 438 K 271 K 496 K 268 K - - - - - - -

Total Inventories

1.63 M 1.68 M 2.16 M 1.98 M 1.36 M 876 K 891 K 1.95 M - - - - - - -

All numbers in USD currency

Quarterly Cash Flow electroCore

2026-Q2 2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

-6.53 M -3.01 M - - -4.36 M - - - -2.56 M - - - -5.86 M - -12.6 M - -4.78 M - -9.27 M - -4.16 M - -16.5 M -12.5 M -8.49 M - -36 M -27.7 M -16.4 M - -34.9 M -21 M -9.68 M - -17.3 M -10.7 M - - - - - - - - - - - - - - - - - - - - - - - - -

Depreciation & Amortization

27 K 21 K - - - - - - 206 K - - - 122 K - 400 K - 106 K - 287 K - 96 K - 289 K 194 K 97.4 K - 152 K 25.5 K 25.5 K - 20.7 K 10.7 K 7.21 K - 7.87 K 8.1 K - - - - - - - - - - - - - - - - - - - - - - - - -

Accounts Payables

2.18 M 2.17 M 3.07 M 2.57 M 1.76 M 1.83 M 1.24 M 1.46 M 2.32 M 2.16 M 3.03 M 2.28 M 2 M 2.13 M 1.9 M - 2.24 M 938 K 1.25 M 2.3 M 2.11 M 2.08 M 2.08 M 2.08 M 2.08 M 5.21 M 5.21 M 5.21 M 5.21 M 2.7 M 2.7 M 2.7 M 2.7 M 840 K 840 K 840 K - - - - - - - - - - - - - - - - - - - - - - - - -

Accounts Receivables

909 K 872 K 1.48 M 813 K 1.46 M 1.37 M 552 K 538 K 475 K 717 K 589 K 238 K 213 K 401 K 364 K - 364 K 438 K 330 K 369 K 259 K 271 K 271 K 271 K 271 K 496 K 496 K 496 K 496 K 268 K 268 K 268 K 268 K 103 K 103 K 103 K - - - - - - - - - - - - - - - - - - - - - - - - -

Total Inventories

2.42 M 1.98 M 1.21 M 1.43 M 1.73 M 1.68 M 1.96 M 2.58 M 2.51 M 2.16 M 2.5 M 2.37 M 2.48 M 1.98 M 1.97 M - 1.58 M 1.36 M 1.08 M 1.08 M 945 K 876 K 876 K 876 K 876 K 891 K 891 K 891 K 891 K 1.95 M 1.95 M 1.95 M 1.95 M 328 K 328 K 328 K - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company electroCore, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Medical instruments sector

Issuer Price % 24h Market Cap Country
BioLife Solutions BioLife Solutions
BLFS
$ 36.38 0.54 % $ 1.74 B usaUSA
Ekso Bionics Holdings Ekso Bionics Holdings
EKSO
- - $ 28.6 M usaUSA
The Cooper Companies The Cooper Companies
COO
$ 71.17 0.3 % $ 14.2 B usaUSA
Atrion Corporation Atrion Corporation
ATRI
- - $ 810 M usaUSA
Isoray Isoray
ISR
- 0.03 % $ 108 M usaUSA
Merit Medical Systems Merit Medical Systems
MMSI
$ 90.49 1.06 % $ 5.35 B usaUSA
AtriCure AtriCure
ATRC
$ 48.54 2.28 % $ 2.32 B usaUSA
Nephros Nephros
NEPH
$ 4.55 5.57 % $ 48.3 M usaUSA
Haemonetics Corporation Haemonetics Corporation
HAE
$ 103.96 0.03 % $ 4.9 B usaUSA
Predictive Oncology Predictive Oncology
POAI
- - $ 31.1 M usaUSA
Glaukos Corporation Glaukos Corporation
GKOS
$ 179.87 0.74 % $ 10.3 B usaUSA
Harvard Bioscience Harvard Bioscience
HBIO
$ 7.93 0.38 % $ 352 M usaUSA
AngioDynamics AngioDynamics
ANGO
$ 15.85 0.44 % $ 658 M usaUSA
NeuroMetrix NeuroMetrix
NURO
- 5.05 % $ 9.02 M usaUSA
ICU Medical ICU Medical
ICUI
$ 175.1 0.43 % $ 4.31 B usaUSA
InfuSystem Holdings InfuSystem Holdings
INFU
$ 12.04 0.12 % $ 249 M usaUSA
iRhythm Technologies iRhythm Technologies
IRTC
$ 120.25 3.37 % $ 3.85 B usaUSA
STERIS plc STERIS plc
STE
$ 233.78 0.35 % $ 23 B usaUSA
Pro-Dex Pro-Dex
PDEX
$ 62.56 1.6 % $ 206 B usaUSA
Baxter International Baxter International
BAX
$ 26.13 0.81 % $ 13.4 B usaUSA
Repligen Corporation Repligen Corporation
RGEN
$ 176.27 0.96 % $ 9.91 M usaUSA
Pulse Biosciences Pulse Biosciences
PLSE
$ 47.57 0.04 % $ 3.21 B usaUSA
ResMed ResMed
RMD
$ 240.33 1.94 % $ 35 B usaUSA
Intuitive Surgical Intuitive Surgical
ISRG
$ 372.6 1.51 % $ 133 B usaUSA
DENTSPLY SIRONA DENTSPLY SIRONA
XRAY
$ 11.12 0.72 % $ 2.22 B usaUSA
Milestone Scientific Milestone Scientific
MLSS
$ 0.5 0.36 % $ 41 M usaUSA
Alcon Alcon
ALC
$ 72.01 0.07 % $ 35.5 B schweizSchweiz
West Pharmaceutical Services West Pharmaceutical Services
WST
$ 337.47 0.11 % $ 24.4 B usaUSA
Envista Holdings Corporation Envista Holdings Corporation
NVST
$ 27.13 0.02 % $ 4.56 B usaUSA
Masimo Corporation Masimo Corporation
MASI
- - $ 9.59 B usaUSA
Microbot Medical Microbot Medical
MBOT
$ 1.48 0.33 % $ 67.8 M israelIsrael
STAAR Surgical Company STAAR Surgical Company
STAA
$ 22.11 0.09 % $ 1.1 B usaUSA
Stereotaxis Stereotaxis
STXS
$ 1.45 0.34 % $ 132 M usaUSA
Repro Med Systems Repro Med Systems
KRMD
$ 3.23 0.94 % $ 149 M usaUSA
OraSure Technologies OraSure Technologies
OSUR
$ 3.6 0.13 % $ 265 M usaUSA
Teleflex Incorporated Teleflex Incorporated
TFX
$ 139.67 1.42 % $ 6.23 B usaUSA
LeMaitre Vascular LeMaitre Vascular
LMAT
$ 80.45 0.99 % $ 1.82 B usaUSA
Becton, Dickinson and Company Becton, Dickinson and Company
BDX
$ 189.52 0.74 % $ 54.5 B usaUSA
Retractable Technologies Retractable Technologies
RVP
$ 0.73 1.14 % $ 21.9 M usaUSA
Utah Medical Products Utah Medical Products
UTMD
$ 72.77 1.35 % $ 236 M usaUSA